Jakavi

Jakavi

ruxolitinib

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ruxolitinib phosphate
Indications/Uses
Disease-related splenomegaly or symptoms in patients w/ high or intermediate risk myelofibrosis including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Patients w/ polycythemia vera who are resistant to or intolerant of hydroxyurea. 
Dosage/Direction for Use
Myelofibrosis Initial dose: Platelet count >200,000/mm3 20 mg bid. Platelet count between 100,000/mm3 & 200,000/mm3 15 mg bid. Platelet count between 50,000/mm3 & 100,000/mm3 Max: 5 mg bid. Dose reductions should be considered if the platelet counts decrease <100,000/mm3. Max dose: 25 mg bid. Polycythemia vera Initially 10 mg bid. Dose reduction should be considered if Hb decreases 10-12 g/dL. Max dose: 25 mg bid. Severe renal impairment  Myelofibrosis Starting dose based on platelet count should be reduced by approx 50%. Polycythemia vera 5 mg bid. Patients w/ ESRD on hemodialysis Myelofibrosis Initially 15 or 20 mg based on platelet counts w/ subsequent single doses only after each dialysis session. Polycythemia vera 10 mg or 2 doses of 5 mg given 12 hr apart administered post-dialysis & only on the day of haemodialysis.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Perform CBC prior to initiation of therapy. Thrombocytopenia in patients w/ low platelet counts (<200,000/mm3); platelet transfusion may be required. Blood transfusion in patients developing anemia. Temporarily discontinue if neutropenia (absolute neutrophil count <500/mm3) occurs. Assess patients for risk of developing serious bacterial, mycobacterial, fungal & viral infections. Herpes zoster. Progressive multifocal leukoencephalopathy. Periodic skin exam for patients who are at increased risk for skin cancer. Severe renal & hepatic impairment. Pregnancy & lactation. Childn.
Adverse Reactions
UTI; anemia, thrombocytopenia, neutropenia; wt gain, hypercholesterolemia, hypertriglyceridemia; dizziness, headache; increased ALT & AST; bruising.
Drug Interactions
Increased AUC & prolonged t½ w/ strong CYP3A4 inhibitors. Increased AUC w/ erythromycin. Decreased AUC & prolonged t½ w/ rifampin.
ATC Classification
L01EJ01 - ruxolitinib ; Belongs to the class of Janus-associated kinase (JAK) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Jakavi tab 5 mg
Packing/Price
14's
Form
Jakavi tab 20 mg
Packing/Price
14's
Form
Jakavi tab 15 mg
Packing/Price
14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in